Pfizer Buys Out All Rights to Exubera

Pfizer buys out partner Sanofi-Aventis for 1.3 billion dollars for global rights to Exubera inhaled insulin treatment.

This may mean:

a.) Pfizer has high hopes for this becoming their blockbuster
b.) Someone has received more good news recently for pending approval (other than September's news from the FDA)
c.) Sanofi-Aventis sold out - why? Investor pressure? Lack of confidence? FDA delays decision and extends review on Exubera...see October '05 story.